Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc (NQ: LTRN )

5.718 -0.312 (-5.17%)
Streaming Delayed Price Updated: 11:24 AM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lantern Pharma Inc

< Previous 1 2 3 Next >
Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Present at The MicroCap Rodeo Presents The Windy City Roundup 2022 on Wednesday, October 12 at 11:00 a.m. ET
Via ACCESSWIRE
Lantern Pharma to Present at Upcoming Investor Conferences
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma CEO & President, Panna Sharma, to Speak at H.C. Wainwright’s 24th Annual Global Investment Conference in September 2022
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Management to Speak at Multiple Investor and Scientific Conferences in May 2022
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / April 14, 2022 / RedChip Companies, Inc. today announced that Lantern Pharma (NASDAQ:LTRN),a clinical stage biopharmaceutical company using its proprietary RADR® artificial... 
From RedChip
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
RedChip Partners with Benzinga to Host Exclusive Small-Cap CEO Interview Series on January 28
ORLANDO, FL / ACCESSWIRE / January 26, 2022 / RedChip Companies, Inc., an international investor relations, media, and research firm focused on microcap and small-cap companies, is pleased to announce... 
From RedChip
Via AccessWire
36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th - 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be... 
From MicroCap Rodeo
Via AccessWire
Lantern Pharma to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Wednesday, October 6, 2021
DALLAS, TX / ACCESSWIRE / September 30, 2021 / Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to... 
From Lantern Pharma
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.